The novel agent most benefited those with low systolic BP, often excluded from major HF trials, but didn t help outcomes when baseline pressures were higher, post hoc analysis of GALACTIC-HF suggests.
Also, no protection was evident at any alcohol-intake level among STOP-HF trial participants who were initially at risk for heart failure but without echocardiographic signs of the disease.
Its impact on mortality, especially when there is right ventricular involvement, can persist after the condition apparently resolves, suggests a meta-analysis.
Speckle-tracking echo picked up early, asymptomatic signs of adverse ventricular remodeling in women with gestational diabetes that were not reliably detected by standard echocardiography.
It s seen as a low-cost way to remotely track patients at increased risk for ventricular dysfunction with 12-lead-ECG accuracy. We can imagine them getting an ECG every day, said one researcher.